Qomel secures SAR 21.6M nupco framework for drug supply

Qomel Co. signed a SAR 21.6 million framework agreement with National Unified Procurement Co. (nupco) on July 6. The arrangement covers the supply of pharmaceuticals on demand. It runs through December 31, 2026.

Nupco is Saudi Arabia's central procurement body for health-sector purchases. For Qomel, a Tadawul-listed pharmaceutical services company, the deal locks in a revenue stream at a time when state healthcare spending is expanding under Vision 2030.

Qomel expects the agreement to affect its financial statements positively starting in the second half of 2026. That timeline reflects the typical lag between signing a framework and the first purchase orders.

The exact revenue contribution will depend on how much nupco orders under the framework. Framework agreements of this type set terms and pricing but leave volume open.

A single government procurement contract of this size can smooth quarterly revenue swings for smaller distributors. Qomel's last audited annual revenue was SAR 380 million, according to its 2024 annual report. The nupco framework, if fully utilized, would represent roughly 5.7% of that base – enough to shift earnings but not transform the business outright.

The stock closed flat on the day of the announcement, suggesting the market had already priced in the deal or is waiting for concrete order flows before re-rating the equity.

Saudi pharmaceutical distributors have been vying for nupco frameworks since the government centralized procurement in 2019. Winning one requires meeting strict local-content and supply-chain standards, which acts as a barrier to smaller competitors. Qomel's inclusion signals it clears those thresholds.